NCT07074327View on ClinicalTrials.gov

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

July 11, 2025

Primary Completion Date

June 29, 2026

Study Completion Date

July 4, 2026

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
DRUG

VX-407

Suspension for oral administration.

DRUG

LNG/EE

Combination Tablets for Oral Administration.

DRUG

NGM/EE

Combination Tablets for Oral Administration.

DRUG

NET/EE

Combination Tablets for Oral Administration.

DRUG

DRSP/EE

Combination Tablets for Oral Administration.

Trial Locations (1)

66212

RECRUITING

Altasciences - Kansas City, Overland Park

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY